Small‑molecule PKR‑like endoplasmic reticulum kinase inhibitors as a novel targeted therapy for Parkinson's disease.
Opis
- Tytuł: Small‑molecule PKR‑like endoplasmic reticulum kinase inhibitors as a novel targeted therapy for Parkinson's disease.
- Autor/Autorzy:
- Nazwa czasopisma: Molecular Medicine Reports
- Rok: 2023
- Tom: 27
- Numer: 5
- ISSN: 1791-2997
- e-ISSN: 1791-3004
- DOI: 10.3892/mmr.2023.12989
- Adres www:: https://www.spandidos-publications.com/mmr/27/5/102
- Strony od-do: 1-15
- Abstrakt: Parkinson's disease (PD) is the second most common neurodegenerative disorder in worldwide and remains a therapeutic challenge due to the low efficacy of current treatments. Numerous studies have demonstrated the pivotal role of endoplasmic reticulum (ER) stress in PD pathogenesis. ER stress, followed by activation of the protein kinase RNA‑like endoplasmic reticulum kinase (PERK)‑dependent branch of the unfolded protein response signaling pathway, ultimately leads to neural cell death and dopaminergic neurodegeneration in PD. Therefore, the present study evaluated the effectiveness of the small‑molecule PERK inhibitor LDN‑87357 in an in vitro PD model using the human neuroblastoma SH‑SY5Y cell line. To assess the mRNA expression levels of the pro‑apoptotic ER stress markers, the TaqMan Gene Expression Assay was performed. Cytotoxicity was assessed using a colorimetric 2,3‑bis‑(2‑methoxy‑4‑nitro‑5‑sulfophenyl)‑ 2H‑tetrazolium‑5‑carboxanilide assay and apoptosis was assessed using a caspase‑3 assay. Moreover, cell cycle progression was evaluated using flow cytometry. The results indicated that LDN‑87357 treatment induced a significant decrease in ER stress markers gene expression in SH‑SY5Y cells exposed to ER stress. Furthermore, LDN‑87357 significantly increased viability, diminished apoptosis and restored the normal cell cycle distribution of SH‑SY5Y cells after ER stress induction. Therefore, the evaluation of small‑molecule PERK inhibitors, such as LDN‑87357, may lead to the development of novel therapeutic strategies against PD.
- Dyscyplina: nauki medyczne
MARC
- 002 a Small‑molecule PKR‑like endoplasmic reticulum kinase inhibitors as a novel targeted therapy for Parkinson's disease.
- 003 b 0000-0001-8757-6958
- 003 a EWA KUCHARSKA (Autor)
- 003 a Grzegorz Galita (Autor)
- 003 a Ireneusz Majsterek (Autor)
- 003 a Natalia Siwecka (Autor)
- 003 a Weronika Lusa (Autor)
- 003 a Wioletta Rozpędek- Kamińska (Autor)
- 004 a Oryginalny artykuł naukowy
- 006 a Molecular Medicine Reports
- 008 a 2023
- 009 a 27
- 010 a 5
- 011 a 1791-2997
- 012 a 1791-3004
- 013 a 10.3892/mmr.2023.12989
- 014 a https://www.spandidos-publications.com/mmr/27/5/102
- 015 a 1-15
- 020 a Parkinson's disease (PD) is the second most common neurodegenerative disorder in worldwide and remains a therapeutic challenge due to the low efficacy of current treatments. Numerous studies have demonstrated the pivotal role of endoplasmic reticulum (ER) stress in PD pathogenesis. ER stress, followed by activation of the protein kinase RNA‑like endoplasmic reticulum kinase (PERK)‑dependent branch of the unfolded protein response signaling pathway, ultimately leads to neural cell death and dopaminergic neurodegeneration in PD. Therefore, the present study evaluated the effectiveness of the small‑molecule PERK inhibitor LDN‑87357 in an in vitro PD model using the human neuroblastoma SH‑SY5Y cell line. To assess the mRNA expression levels of the pro‑apoptotic ER stress markers, the TaqMan Gene Expression Assay was performed. Cytotoxicity was assessed using a colorimetric 2,3‑bis‑(2‑methoxy‑4‑nitro‑5‑sulfophenyl)‑ 2H‑tetrazolium‑5‑carboxanilide assay and apoptosis was assessed using a caspase‑3 assay. Moreover, cell cycle progression was evaluated using flow cytometry. The results indicated that LDN‑87357 treatment induced a significant decrease in ER stress markers gene expression in SH‑SY5Y cells exposed to ER stress. Furthermore, LDN‑87357 significantly increased viability, diminished apoptosis and restored the normal cell cycle distribution of SH‑SY5Y cells after ER stress induction. Therefore, the evaluation of small‑molecule PERK inhibitors, such as LDN‑87357, may lead to the development of novel therapeutic strategies against PD.
- 022 a apoptosis
- 022 a endoplasmic reticulum stress
- 022 a neurodegeneration
- 022 a Parkinson's disease
- 022 a Parkinson's disease treatment
- 022 a protein kinase RNA‑like endoplasmic reticulum kinase
- 022 a small‑molecule PERK inhibitor
- 022 a unfolded protein response
- 966 a nauki medyczne
- 985 a Wydział Pedagogiczny
- 985 b Instytut Nauk o Wychowaniu
Dublin Core
Indeksy
- Tytuł: Small‑molecule PKR‑like endoplasmic reticulum kinase inhibitors as a novel targeted therapy for Parkinson's disease.
- Autor (Twórca):
- Tytuł czasopisma : Molecular Medicine Reports
- Data: 2023
- Dyscyplina: nauki medyczne
- Słowa kluczowe w j. angielskim:
- Struktura: